-
公开(公告)号:US10308597B2
公开(公告)日:2019-06-04
申请号:US15307178
申请日:2015-04-30
申请人: Rgenix, Inc.
IPC分类号: C07C279/14 , C07D233/46 , A61K31/4168 , C07D239/14 , A61K31/505 , C07D233/06 , C07D253/06 , A61K31/53 , A61K31/155 , C07D213/74 , A61K31/4402 , C07C279/16 , C07C313/34 , C07F9/48 , C07F9/09 , C07F9/24 , C07F9/38 , C07F9/40 , A61K31/00 , C07D213/76 , C07C257/14 , C07C259/14 , C07C279/26 , C07C279/36 , C07C281/16 , C07C281/18 , C07D231/12 , C07C309/15 , C07D233/26 , C07D233/52 , C07D233/64 , C07D233/88 , C07D401/04 , C07D239/06 , C07D405/04 , C07D249/08 , C07D249/14 , C07D257/08 , C07D487/04 , C07D205/04 , C07D207/16 , C07D207/22 , C07D295/32 , A61K31/397 , A61K31/40 , A61K31/4427 , A61K31/7068 , A61K45/06 , C07C275/70 , C07D205/08 , C07H19/06 , A61K31/337 , A61K31/704 , A61K31/7105 , C07F9/568 , C07F9/572 , C07F9/6506
摘要: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
-
公开(公告)号:US20190315680A1
公开(公告)日:2019-10-17
申请号:US16389008
申请日:2019-04-19
申请人: Rgenix, Inc.
IPC分类号: C07C279/14 , C07D253/06 , C07C279/16 , C07C313/34 , C07F9/6506 , C07F9/572 , C07F9/568 , A61K31/7105 , A61K31/704 , A61K31/337 , A61K31/155 , A61K31/53 , A61K31/7068 , A61K45/06 , C07C275/70 , C07D205/08 , C07D213/74 , C07H19/06 , A61K31/397 , A61K31/40 , A61K31/4168 , A61K31/4402 , A61K31/4427 , A61K31/505 , C07D295/32 , C07D207/22 , C07D207/16 , C07D205/04 , C07D487/04 , C07D257/08 , C07D249/14 , C07D249/08 , C07D239/14 , C07D405/04 , C07D239/06 , C07D401/04 , C07D233/88 , C07D233/64 , C07D233/52 , C07D233/46 , C07D233/26 , C07C309/15 , C07D231/12 , C07C281/18 , C07C281/16 , C07C279/36 , C07C279/26 , C07C259/14 , C07C257/14 , C07D213/76 , A61K31/00 , C07F9/40 , C07F9/38 , C07F9/24 , C07F9/09 , C07F9/48
摘要: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
-
公开(公告)号:US20200255543A1
公开(公告)日:2020-08-13
申请号:US16626456
申请日:2018-06-26
摘要: The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosin Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.
-
公开(公告)号:US10717704B2
公开(公告)日:2020-07-21
申请号:US16389008
申请日:2019-04-19
申请人: Rgenix, Inc.
IPC分类号: A61K31/7105 , A61K31/704 , A61K31/337 , A61K31/155 , A61K31/53 , A61K31/7068 , A61K45/06 , A61K31/397 , A61K31/40 , A61K31/4168 , A61K31/4402 , A61K31/4427 , A61K31/505 , C07C279/14 , C07C279/16 , C07C313/34 , C07F9/48 , C07F9/09 , C07F9/24 , C07F9/38 , C07F9/40 , A61K31/00 , C07D213/76 , C07C257/14 , C07C259/14 , C07C279/26 , C07C279/36 , C07C281/16 , C07C281/18 , C07D231/12 , C07C309/15 , C07D233/26 , C07D233/46 , C07D233/52 , C07D233/64 , C07D233/88 , C07D401/04 , C07D239/06 , C07D405/04 , C07D239/14 , C07D249/08 , C07D249/14 , C07D253/06 , C07D257/08 , C07D487/04 , C07D205/04 , C07D207/16 , C07D207/22 , C07D295/32 , C07F9/568 , C07F9/572 , C07F9/6506 , C07C275/70 , C07D205/08 , C07D213/74 , C07H19/06
摘要: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
-
公开(公告)号:US10669296B2
公开(公告)日:2020-06-02
申请号:US15110343
申请日:2015-01-09
申请人: Rgenix, Inc.
发明人: Eduardo J. Martinez , Bernd Kaiser , Sohail F. Tavazoie , Isabel Kurth , Foster Casimir Gonsalves , David M. Darst, Jr. , Masoud Fakhr Tavazoie
IPC分类号: A61K45/06 , A61K31/165 , A61K31/445 , A61K31/138 , A61K31/195 , A61K31/145 , A61K31/24 , A61K31/357 , A61K31/675 , A61K31/661 , A61K31/40 , A61K31/397 , A61K31/366 , C07C259/06 , C07C311/51 , C07C317/22 , C07C317/46 , C07C317/14 , C07C317/04 , C07C217/18 , C07C217/20 , C07C217/22 , C07C217/58 , C07C323/32 , C07C323/09 , C07D311/76 , C07D317/46 , C07D205/04 , C07D207/48 , C07D209/48 , C07D211/42 , C07D211/96 , C07F9/12 , C07F9/09 , C07B59/00 , C07F9/6571 , C07F9/6574 , C07F9/30
摘要: This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.
-
-
-
-